(SGMO) traded up $0.35 on Thursday, reaching $12.30. Aveo Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $329.29 Million and most recently 112.77 Million outstanding shares have been calculated. Northern Trust Corp increased its position in Sangamo Therapeutics by 4.9% during the second quarter. Piper Jaffray Cos. cut shares of Sangamo BioSciences from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $9.00 to $5.00 in a report on Wednesday, October 19th. Geode Capital Management LLC now owns 633,964 shares of the biopharmaceutical company's stock valued at $3,296,000 after acquiring an additional 19,331 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Sangamo Therapeutics by 2.0% during the 2nd quarter. Moreover, Opaleye Management Inc. has 2.13% invested in the company for 580,000 shares.
Shares of Sangamo Therapeutics (NASDAQ:SGMO) soared 2.93% or 0.35 to reach at $12.3 during previous trading session. (SGMO) has 83.61M billion shares outstanding. Relative strength index (RSI-14) for Sangamo Therapeutics (NASDAQ:SGMO) is at 42.22. The shares were sold at an average price of $14.37, for a total value of $445,470.00. However, the institutional investors are observed to own 64.20% of the total shares. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Curt A. Herberts III sold 11,474 shares of the stock in a transaction dated Monday, August 14th. The stock's last price was lower from the average trading price of 50 days recorded at $28.01 while enlarging the period to 200 trading days, the average price was $27.96. The disclosure for this sale can be found here.
Aveo Pharmaceuticals (NASDAQ:AVEO)'s shares slipped -4.58% in the past week and plunged -22.75% in the last 4 weeks, historically the stock illustrate that its six months performance stands at 408.98% while its year to date performance is at 440.74%. Zacks Investment Research upgraded Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a research report on Friday, August 18th. Finally, BidaskClub downgraded Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, July 28th. The firm has "Buy" rating by Jefferies given on Friday, October 23. Out of 2 Wall Street analysts rating Sangamo BioSci, 0 give it "Buy", 0 "Sell" rating, while 2 recommend "Hold". One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. $13's average target is -3.35% below currents $13.45 stock price.
Shares of Telephone and Data Systems, Inc. Sangamo Therapeutics (NASDAQ:SGMO) has a Return on Assets (ROA) of -30.7. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.14 and a current ratio of 6.14. If the published price targets set by Sangamo Therapeutics, Inc. analysts have any power to influence the stock's share price, the highest price target set for SGMO is $30.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, August 9th.
The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. The mean target price as estimated by the analysts for the company has been recorded at $14.60.
On a similar note, analysts expect EPS of -$0.2 in September 2017 quarter and -$0.23 in December 2017 quarter, representing -25.93% and 64.29% growth, respectively. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of United States of America and worldwide copyright law. "(SGMO) Position Boosted by Vanguard Group Inc." was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal.
Have you taken a look at the chart for Sangamo Therapeutics, Inc. The Firm is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy.